Key facts
- This page summarizes Daniel E. Ryweck's Form 4 filing for Silo Pharma, Inc. (SILO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 27 May 2025, 19:02.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
The options were issued pursuant to the Issuer's 2020 Omnibus Equity Incentive Plan and one hundred percent (100%) of the shares subject to the option shall vest on the one (1)-year anniversary of the date of grant.